Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
J. Immunother. Cancer, Mar 13 2024, 12 (3) e008638 | https://doi.org/10.1136/jitc-2023-008638